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Introduction
Many rheumatological diseases such as systemic lupus erythematosus (SLE), rheumatoid 
arthritis (RA), polymyositis and dermatomyositis, systemic sclerosis, and Sjögren’s 
syndrome predominantly affect females. A considerable proportion of these patients are 
of reproductive age. Conceivably, the female predilection for many of these conditions 
could be because oestrogens play some part in their pathogenesis.1 It has even been 
demonstrated that oestrogen can potentiate the phagocytic and antigen-presenting activity 
of macrophages, promote the maturation of T-helper (Th) cells, and activate polyclonal B-
cells.2 Hence, the use of oestrogen-containing compounds such as combined hormonal 
contraceptives and hormone replacement therapy, or hormone therapy (HT) which is 
the terminology now preferred, would theoretically aggravate these conditions and raise 
concerns among doctors taking care of such patients.
 For women who have no plans for pregnancy or those whose disease status deems 
them unfit for pregnancy, a safe and effective contraceptive choice is obviously needed. 
Owing to the complexity of these disease entities and the limited scientific evidence 
available in the literature, there have been many myths and controversies among 
rheumatologists and gynaecologists alike over the use of hormonal contraceptives, 
especially the combined oestrogen-progestogen preparations. As a result, these women, 
particularly those suffering from SLE, have often been denied of the use of hormonal 
contraception, despite the very effective and reversible protection from pregnancy it can 
provide. 
 Additionally, women with autoimmune conditions are more prone to premature 
ovarian failure as a result of their disease or its treatment with cytotoxic agents. Accord-
ingly, they are at risk of developing premature osteoporosis, which may also be related 
to glucocorticoid use. The use of HT in these circumstances is yet another controversial 
issue.
 The aim of this article was to review the most up-to-date evidence regarding the use 
of hormonal contraception and HT in patients with rheumatological diseases and provide 
some guidance in clinical management.
Methods
A search in PubMed was performed using the terms “contraception” or “contraceptive”, 
“hormone replacement therapy” in combination with “lupus”, “rheumatoid arthritis”, 
“polymyositis”, “dermatomyositis”, “systemic sclerosis” and “Sjögren’s syndrome”. 
Systematic reviews and randomised controlled trials published between 1990 and 
December 2010 were searched and reviewed.
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A number of rheumatological diseases predominantly affect women of reproductive age. 
There has always been concern that the use of oestrogen-containing agents such as combined 
hormonal contraception and hormone therapy might aggravate these conditions. This 
article reviews the up-to-date evidence regarding the safety of using these agents in women 
with various rheumatological diseases, with emphasis on systemic lupus erythematosus 
and rheumatoid arthritis. In the absence of antiphospholipid antibody or other pro-
thrombotic risk factors, combined hormonal contraception is not contra-indicated in most 
rheumatological conditions including inactive systemic lupus erythematosus. Moreover, 
hormone therapy is generally not contra-indicated except for women with active systemic 















Systemic lupus erythematosus is more prevalent 
in females than males with a ratio of approximately 
9:1. It is one of the most common rheumatological 
diseases affecting women of reproductive age, for 
which the use of sex steroids poses a concern.1 
Oestrogen and pregnancy shifts the balance of Th1/
Th2 cytokine production towards the latter, and as SLE 
is predominantly a Th2 cytokine–mediated condition, 
theoretically it is prone to aggravation if tissues have 
high oestrogen content.2 
 In women who consider using oestrogen-
containing compounds, an important consideration 
is the presence of antiphospholipid antibodies (APL 
Abs). Antiphospholipid antibodies, including lupus 
anticoagulant and anticardiolipin antibody, are 
commonly found among patients with autoimmune 
diseases, particularly SLE. Women who are positive 
for APL Abs are prone to both arterial and venous 
thromboembolism (VTE), and oestrogen-containing 
contraceptives and HT are therefore contra-indicated 
in these women.
Hormonal contraception
Large case-control studies suggested that current 
but not past use of combined oral contraceptives 
(COC) is associated with an increased incidence 
of SLE.3,4 The risk appeared higher in those using 
second-generation and high-dose pills.4 A recently 
published systematic review on the use of hormonal 
contraception in SLE assessed 13 studies,5 including 
two good-quality randomised controlled trials 
(RCTs).6,7 This incorporated all currently published 
clinical trials relevant to this topic, and its main 
findings are summarised as follows.
Disease activity
The two available randomised trials6,7 indicated that 
the use of COC did not lead to increased flares of 
disease or worsening activity in women with inactive 
or stably active SLE. Nor did use of progestogen-only 
pills (POP) lead to increased disease activity.
Thromboembolic risk
For patients who are APL Ab–positive, the use of COC 
adds to the risk of both arterial and VTE5,8 and is not 
recommended. For those without such antibodies, 
there is no adequate good-quality evidence. One 
RCT7 reported four VTE events out of 162 women, 
two of whom used COC and the other two used 
POP, versus none in those using an intrauterine 
contraceptive device. However, all the four patients 
were APL Ab–positive. Another RCT6 reported five 
VTE events out of 183 women with SLE, two using 
COC and three using placebo, but the APL Ab status 
of these subjects was unknown. A potential bias with 
these studies was that women at very high risk of VTE 
were probably already excluded from the studies, 
and hence the results may not be applicable to all 
SLE patients.
Musculoskeletal complications
One RCT9 revealed that COC use reduced the risk 
of musculoskeletal problems (eg muscular atrophy 
or weakness, deforming arthritis, osteoporosis, 
vertebral collapse or fracture, avascular necrosis, 
osteomyelitis and ruptured tendon). Another 
retrospective analysis10 of 702 SLE patients showed 
that ever users of COC (type of COC not specified) 
had a significantly lower fracture risk compared with 
never users (53% vs 64%).
Recommendations
Based on the available results from these studies, the 
World Health Organization (WHO) has recently added 
the guidance on the use of contraceptive methods 
in SLE in the updated medical eligibility criteria 
(Table11). In summary, use of any form of hormonal 
contraception is not contra-indicated in women with 
inactive or stably active SLE, with the exception of 
those whose APL Ab status is positive (or unknown). 
In the latter condition, combined hormonal 
contraception in any form is absolutely contra-
indicated (WHO 4), and the use of progestogen-only 
contraception is relatively contra-indicated (WHO 
3). Meanwhile, women with SLE may have other co-
existing cardiovascular risk factors that also need to 
be taken into consideration and checked with the 
WHO guideline,11 when deciding on the individual’s 
medical eligibility for using hormonal contraception.
Hormone therapy
The interaction between HT and SLE is another 
difficult area. Two prospective studies have reported 
a significant increase in the incidence of new disease 
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in HT users, and the risk increased with increasing 
duration of use.12 However, some retrospective 
studies suggested no increase in clinical flares.12 
These issues have been the subject of review.12 
 The best evidence was from the double-blind 
RCT with the acronym SELENA (Safety of Estrogens 
in Lupus Erythematosus, National Assessment) trial.13 
It investigated 351 women with inactive disease, who 
started combined cyclical HT or placebo. The women 
were APL Ab–negative and had no history of VTEs. 
There was no difference in the risk of severe flares 
between the respective groups (7.5% vs 4.5%; odds 
ratio [OR]=1.75; 95% confidence interval [CI], 0.73-
4.22), whereas there was a small increase in risk of 
mild-to-moderate flares (OR=1.34; 95% CI, 1.07-1.66). 
A few cases of arterial and venous thrombotic events 
including one death, three deep venous thromboses 
(DVTs), one stroke, and one arteriovenous graft 
thrombosis were reported in the HT group, as well 
as one DVT in the placebo group. The dropout rate 
in the study was high, and the overall evidence 
was inconclusive. Although the evidence seemed 
reassuring for severe flares, the risk of milder flares 
and VTEs was less clear. Moreover, in view of the trial’s 
exclusion criteria, the results were not applicable to 
women with active disease or at high thrombotic 
risk. Some other smaller studies did not show any 
increased risk of SLE flares with HT use.14-17 
 One case-control study included women who 
were APL Ab–positive.18 No difference in incidence 
or timing for the development of coronary heart 
disease (CHD) was found between the 114 HT users 
and 227 non-users. Multivariate analysis revealed 
that age, but not HT use, was associated with CHD 
development.
 With regard to other compounds related to 
HT, a recent small RCT of 30 women with inactive or 
stable SLE suggested that the use of tibolone did not 
increase flares compared to placebo.19 A small RCT20 
among 16 women with SLE taking raloxifene versus 17 
taking on placebo revealed no significant difference 
in disease activity when followed up to 1 year, and 
there was no VTE. There are currently no safety data 
on the use of androgens in women with connective 
tissue diseases. Theoretically, testosterone may be 
aromatised to oestrogen, and hence its use is not 
recommended until more data are available.
Recommendations
In general, the use of HT should be tailored to 
individual risks and benefits with reference to the 
SLE disease activity profile and symptomatology. The 
main indication of HT should be severe climacteric 
symptoms impairing quality of life. Hormone therapy 
can be used when SLE is inactive with no flares for 
several years, and in women who are APL Ab–negative 
and not on high-dose steroids. For such women, low-
dose transdermal oestrogen combined with a natural 
progesterone preparation is preferred as it is less 
thrombogenic.21 Similarly, it has been suggested that 
micronised progesterone or pregnane derivatives 
did not result in increased thromboembolic risk, 
whereas norpregnane derivatives were associated 
with a 4-fold increase in VTE risk.22 
 For those with mildly active disease, a 
non-oestrogenic agent (eg antidepressant or 
progestogen) is the preferred first-line treatment. 
If this is not effective, low-dose transdermal HT can 
be used with close monitoring of disease activity. 
For those with severe active disease or who are 
APL Ab–positive, HT should be avoided. The use of 
HT in those with premature ovarian failure should 
generally be beneficial and is recommended.
Rheumatoid arthritis
Rheumatoid arthritis occurs 2 to 3 times more 
commonly in women than in men. Disease severity 
* COC denotes combined oral contraceptives, CIC combined injectable contraceptives, POP progestogen-only pills, IUCD intrauterine contraceptive device, 
I initiation, and C continuation
†  Categories: 1 = no restriction for the use of the method; 2 = the advantages of using the method generally outweigh the theoretical or proven risks; 3 = the 
theoretical or proven risks usually outweigh the advantages of using the method (ie relatively contra-indicated); 4 = unacceptable health risk if the method is 
used (ie absolutely contra-indicated)
‡ Severe thrombocytopaenia increases the risk of bleeding. The category should be assessed according to the severity of thrombocytopaenia and its clinical 
manifestations. In women with very severe thrombocytopaenia who are at risk for spontaneous bleeding, consultation with a specialist and certain pre-
treatments may be warranted
TABLE. Medical eligibility criteria for contraceptive use in patients with systemic lupus erythematosus*11
Condition Categories of medical eligibility criteria†
COC, 
patch, ring
CIC POP Progestogen-only 
injectables
Implants Copper IUCD Levonorgestrel 
intrauterine system
I C I C
Positive (or unknown) 
antiphospholipid antibodies
4 4 3 3 3 3 1 1 3
Severe thrombocytopaenia 2 2 2 3 2 2 3‡ 2‡ 2‡
Immunosuppressive treatment 2 2 2 2 2 2 2 1 2
None of the above 2 2 2 2 2 2 1 1 2
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tends to diminish during pregnancy and hence there 
is some suggestion of hormone dependence. As RA 
is a Th1 cytokine–mediated condition, high oestrogen 
exposure should theoretically ameliorate disease 
activity.2
Hormonal contraception
There is some evidence that past users of COC have a 
lower incidence of RA, whereas other reports suggest 
no such protective effect.23 A recent systematic review 
on the safety of hormonal contraceptives in women 
suffering from RA included only six relevant articles.24 
All available data were on the COC pill. The only fair-
quality prospective cohort study in 112 women with 
RA showed a trend towards improvement in both 
objective and subjective measures of RA symptoms, 
but was underpowered and the result did not reach 
statistical significance. The other five poor-quality 
studies showed either little or no effect of COC use 
on disease progression. 
Recommendations
As the current limited evidence does not suggest any 
adverse effect of COC use on disease progression, 
there should be no contra-indication in RA patients. 
There are currently no data on the use of other 
forms of hormonal contraceptives in women with 
RA. Women with RA are more prone to osteoporosis 
either due to the disease activity or use of systemic 
steroids. There is an established association between 
a reversible decrease in bone mineral density (BMD) 
and the use of depot medroxyprogesterone acetate.25 
Its clinical significance in RA patients is uncertain 
however. Individualised clinical judgement should 
be exercised.
Hormone therapy
According to one RCT involving 88 postmenopausal 
women, using HT significantly ameliorated 
symptoms, disease activity scores and radiological 
disease progression, and improved BMD.26 Another 
four RCTs did not confirm any statistically significant 
difference in symptom severity in HT users versus 
non-users, although in one of the studies there was 
significant improvement in symptoms after women 
with poor compliance were excluded.27-30
Recommendations
As the use of HT in women with RA was not shown 
to aggravate disease activity, and there was some 
suggestion of improvement, HT is not contra-
indicated when treatment appears necessary. There 
has not been adequate evidence on the use of HT 
in postmenopausal women with RA for specific 
prophylaxis against osteoporosis.
Other rheumatological conditions
There are currently no clinical safety data on the 
use of hormonal contraception and HT in other 
rheumatological conditions such as dermatomyositis, 
Sjögren’s syndrome and systemic sclerosis, 
which also occur more commonly in women of 
reproductive age. As these diseases are not generally 
oestrogen-related, the use of sex steroids in affected 
women is probably safe, provided any co-existing 
hypercoagulable state or other contra-indications are 
absent. Antiphospholipid antibodies are commonly 
found in various autoimmune diseases and should be 
ruled out before exogenous sex steroids can be safely 
prescribed. In women with Raynaud’s phenomenon, 
oestrogen has been found to have a vasodilator 
effect and may improve symptoms.31 Patients using 
long-term glucocorticoids are prone to osteoporosis. 
There is some suggestion that HT use improves 
BMD in glucocorticoid users, although the effect on 
fracture prevention is unclear.32 Bisphosphonates 
are generally considered to be the evidence-based 
first-line option for the prevention and treatment 
of glucocorticoid-induced osteoporosis, but in 
hypoestrogenic women with climacteric symptoms, 
HT can be considered.32
Conclusion
Women with rheumatological conditions have the 
same needs for safe and effective contraceptive 
choices as the general population. Clinicians should 
fully understand the advantages and drawbacks of 
each contraceptive method, the effect of the different 
methods on disease activity and other health risks, 
the possibility of interactions with concurrent 
medications, and the needs and preferences of 
the couple. Combined hormonal contraception is 
effective, convenient, and reversible. It is not contra-
indicated in most autoimmune conditions including 
inactive SLE in the absence of APL Abs or other pro-
thrombotic risk factors. For women in whom the use 
of oestrogen is a concern, progestogen-only methods 
can be considered, except that BMD loss associated 
with progestogen-only injectables impose some 
concern in women with a co-existing predisposition to 
osteoporosis. For women who need HT, it is generally 
not contra-indicated except in those with active SLE 
disease for whom physicians must exercise individual 
judgement. Nonetheless, the guiding principles in 
prescribing hormonal contraceptives and HT for 
the general population should also apply to women 
with rheumatological conditions. They should always 
be reviewed in the context of co-existing medical 
conditions and other risk factors which favour or 
contra-indicate the use of hormonal agents. By this 
means, the balance between benefits and risks can 
be properly assessed and compared against all other 
available alternative treatment options.
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